In 2017, a large study of over 280,000 British and Spanish patients found no increased risk of venous thromboembolism in users of strontium ranelate compared to alendronate. Servier ceased manufacturing the drug and in 2019, the drug returned the market in the United Kingdom under the name Strontium ranelate Aristo.
In 2017, a substantial study of more than 280,000 British and Spanish patients did not reveal an elevated risk of venous thromboembolism in strontium ranelate users compared to alendronate users. Servier halted the drug's production, and in 2019, it re-entered the market in the United Kingdom under the name Strontium ranelate Aristo.